Navigation Links
Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Date:8/23/2007

DUBLIN, Calif., Aug. 23 /PRNewswire/ -- Microchip Biotechnologies, Inc. (MBI) and TEC Edmonton have entered into an exclusive patent license agreement that allows MBI to commercialize a University of Alberta invention that can improve the development of lab-on-a-chip devices and biosampling procedures.

"The licensing of this fundamental patent on manipulating beads on-chip continues to build upon our strong intellectual property position in microfluidic devices," said Stevan Jovanovich, President and CEO of MBI. "Microfluidic devices will play a critical role in next generation instrumentation in delivering fully automated, cost effective solutions life science, applied sciences, and diagnostic products for laboratory and field based applications."

California-based MBI will use the technology patented by TEC Edmonton officially called an Apparatus and Method for Trapping Bead Based Reagents within Microfluidic Analysis Systems (US Patent 6,432,290). A team led by Dr. Jed Harrison, Professor and Chair in the Department of Chemistry, invented the technology to allow trapping of beads on-chip, as well as packing and unpacking the trapping zones, which significantly extends the applications of microfluidic analysis systems, such as those used in biodefense and genomics industries.

Microfluidics deals with the behavior, precise control and manipulation of microliter and nanoliter volumes of fluids and is used in the development of devices such as DNA chips, micro-propulsion, and lab-on-a-chip technology. Microfluidic devices are smaller, faster and cheaper than the desktop counterparts that they are designed to replace.

About TEC Edmonton

TEC Edmonton acts as the exclusive technology transfer office for the University of Alberta, the largest research institution in the province of Alberta with nearly 13,000 academic and support staff and over 36,000 students at its campus in the Province's capital, Edmonton. A joint venture of the University of Alberta and Edmonton Economic Development Corporation, TEC Edmonton is committed to providing investors with access to high-growth, advanced-technology opportunities in the form of new inventions, innovations, or early stage ventures created in the Edmonton region. For more information, visit: http://www.TECedmonton.com.

About Microchip Biotechnologies

Microchip Biotechnologies Inc. is an early-stage privately-held company located in Dublin, California that is developing advanced nanofluidic sample preparation and analytical instrumentation for Life Sciences, Applied Sciences, and Diagnostics markets. These solutions are based on MBI's proprietary "NanoBioProcessorTM platform and associated "Microscale-on-Chip-Valves" (MOVTM). More details can be found on the Company's website: http://www.microchipbiotech.com.


'/>"/>
SOURCE Microchip Biotechnologies
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
2. Perscitus Biosciences secures $250K Commerce loan
3. ProCertus BioPharm secures $2.3M in financing
4. Mirus Bio secures $900K grant to develop research tool
5. BioSystem Development secures angel funding
6. TrafficCast secures $1 million line of credit
7. Medical College secures $9.7M research grant
8. Wausau start up secures $560K for GPS maps
9. Platypus Technologies secures $450K SBIR grant
10. nPoint Secures Second Round of Funding
11. Congresswoman Baldwin secures Federal Funds for UW-Rock County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 Cousins Properties (NYSE: ... world,s leading biotechnology companies, has signed a 10-year, approximately 125,000 ... A office asset located in the Westshore submarket of ... thrilled that Amgen has chosen Corporate Center for their new ... Gellerstedt , president and chief executive officer of Cousins Properties. ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture ... added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... USA ) and the US National Institutes of Health. ... ... Logo ...
(Date:3/27/2017)...  Perthera,s Chief Bioinformatics Officer and research faculty member ... Ph.D., will be speaking at the American Medical Informatics ... 27, 2017, she will be speaking on the topic ... and Care" (from 10:30 a.m. – 12:00 p.m. PST) ... a participant in the "Making Precision Oncology Data More ...
(Date:3/27/2017)... ... , ... PMG Research is pleased to announce its participation in ... Forum in Boston on April 3-4, 2017. The CTC conference focuses on how the ... bring them closer to the patient. Clinical Trial Collaborations also will present an inaugural ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... , Feb. 9, 2017 The biomass ... analysis of the biomass boiler market globally in terms ... of biomass boilers. The market for biomass boilers has ... type, end-user, application, and country/region. The market based on ... & forest residues, biogas & energy crops, urban residues, ...
Breaking Biology News(10 mins):